Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of prediabetes
3.2.1.2 Growing focus on preventive healthcare
3.2.1.3 Innovations in drug formulations
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited awareness and screening
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Biguanides
5.3 Thiazolidinediones
5.4 Glucagon-like peptide-1 agonists (GLP-1)
5.5 Sodium-glucose cotransporter 2 inhibitors (SGLT2)
5.6 Dipeptidyl peptidase-4 inhibitors (DPP-4)
5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Children (12-18 years)
6.3 Adults (18-49)
6.4 Elderly (50+)
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Wholesalers/Distributors
7.3 Retail chain
7.4 Online distribution
7.5 Other distribution channels
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 AstraZeneca PLC
9.3 CH Boehringer Sohn AG & Co KG
9.4 Eli Lilly and Company
9.5 Glenmark Pharmaceuticals Limited
9.6 Johnson & Johnson
9.7 Merck & Co., Inc.
9.8 Novartis AG
9.9 Novo Nordisk A/S
9.10 Pfizer Inc.
9.11 Takeda Pharmaceutical Company LimiteD
